CHPA announces expert speakers from FDA, CFSAN for its annual conference

CHPA announces speakers and agenda for its 2021 Regulatory, Scientific & Quality Conference

The 2021 Regulatory, Scientific & Quality Conference hosted by the Consumer Healthcare Products Association (CHPA; Washington) will be held virtually Sept. 9 – Sept. 10. The event brings together respected experts to discuss timely regulatory, scientific, legal, and product quality topics affecting the consumer healthcare products industry and explore the evolving self-care landscape. 

This year’s virtual RSQ will feature a line-up of speakers from FDA, including:

  • Janet Woodcock, MD, acting commissioner, FDA. Woodcock will provide remarks on FDA priorities with an emphasis on self-care.
  • Cara Welch, PhD, acting director, Office of Dietary Supplement Programs, CFSAN, FDA and Jonette R. Foy, PhD, deputy office director, Office of Policy, CDRH, FDA, who will update participants on CFSAN and CDRH staffing, key accomplishments and challenges, and top priorities in the coming year for dietary supplements and medical devices, respectively.

Attendees can participate in 12+ breakout sessions, featuring 30+ speakers and more than 15 on-demand sessions. This year’s agenda includes:

  • FDA/USP Leadership Panel Discussion: Theresa Michele, MD, director, Office of Nonprescription Drugs, Office of New Drugs, CDER, FDA; Donald D. Ashley, JD, director, Office of Compliance, CDER, FDA; and Jaap Venema, PhD, executive vice president & chief science officer, The United States Pharmacopeial Convention, Inc.
  • The Consumerization of Health Care: John Whyte, MD, chief medical officer, WebMD
  • DSHEA 2.0 - Liz Richardson, project director, Pew Charitable Trusts; Diane McEnroe, JD, partner, Sidley Austin, LLP
  • CBD – Regulatory, Legislative, and Scientific Insights: Duffy MacKay, ND, senior vice president, Scientific & Regulatory Affairs, CV Sciences, Inc.; Pete Meachum, senior director, Government Affairs, Chronos Group; Rend Al-Mondhiry, JD, partner, Amin Talati Wasserman
  • Considerations for the Future of Rx-to-OTC Switches: Bernie Simone, vice president of Client Strategy and Rx-to-OTC Switch, Pinney Associates; Clark Richardson, MPH, president & CEO, PEGUS Research, Inc.; Mary Alice Lawless, founder and chief client officer, Biograph Inc.; Francis E. Becker, MD, FACP, director, Division of Nonprescription Drugs II, Office of Nonprescription Drugs, FDA
  • Innovation Opportunities in Consumer Self-Care: Sonja Fulmer, PhD, assistant director for Digital Health Policy, Center for Devices and Radiological Health, FDA; and Jenna Phillips, MSc, principal consultant, PA Consulting
  • Impurities: David Light, founder and CEO, Valisure; Amy L. Roe, principal scientist, The Procter & Gamble Company; Antonio Hernandez-Cardoso, principal scientist, The United States Pharmacopeial Convention, Inc.

There will be breakout sessions in three categories: dietary supplements, quality, and regulatory. For a full list of speakers and an agenda, visit CHPA’s event page.